Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: nanoparticle viral therapies - NanoViricides

Drug Profile

Research programme: nanoparticle viral therapies - NanoViricides

Alternative Names: Anti-HCV nanoviricide (HepCCide); Antiviral nanomedicines - NanoViricides; AviFluCide I; AviFluCide-HP; EbolaCide; EkC-Cide; EKC-Cide-I; EkCCide; FluCide; FluCide anti-influenza drug candidates - NanoViricides; FluCide I; FluCide-HP; HepCCide; HerpeCide; Herpicide; Herpicide-I; HIVCide; HivCide-I; HiviCide I; HiviCide-II; Injectable FluCide™; MERS-CoV therapeutic - NanoViricides; Nanoviricides®; NV-INF-1; NV-INF-2; Oral FluCide™ anti-influenza drug candidates - NanoViricides; RabiCide-I

Latest Information Update: 03 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NanoViricides
  • Developer Baylor College of Medicine; NanoViricides; Southern Research Institute; SUNY Upstate Medical University; United States Army Medical Research Institute of Infectious Diseases; University of California at San Francisco; University of Pittsburgh; University of Wisconsin-Madison
  • Class Antivirals; Polymers; Viral fusion proteins
  • Mechanism of Action CCR5 receptor modulators; CD4 antigen modulators; CXCR4 receptor modulators; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dendritic keratitis; Ebola virus infections; Herpes simplex virus infections; HIV-1 infections; Infectious keratoconjunctivitis; Influenza virus infections; Retinal disorders; Varicella zoster virus infections
  • Research Zika virus infection
  • Suspended Hepatitis C
  • No development reported Middle East respiratory syndrome coronavirus; Rabies

Most Recent Events

  • 26 Jun 2018 NanoViricides plans to submit IND to USFDA for Herpes simplex virus infections
  • 26 Jun 2018 Pharmacodynamics and adverse events data from in vitro studies in Herpes simplex virus infections released by NanoViricide
  • 21 Feb 2018 Interim pharmacodynamics data from a preclinical study in Varicella zoster virus infections released by NanoViricides
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top